JP7784430B2 - 新規化合物 - Google Patents
新規化合物Info
- Publication number
- JP7784430B2 JP7784430B2 JP2023537723A JP2023537723A JP7784430B2 JP 7784430 B2 JP7784430 B2 JP 7784430B2 JP 2023537723 A JP2023537723 A JP 2023537723A JP 2023537723 A JP2023537723 A JP 2023537723A JP 7784430 B2 JP7784430 B2 JP 7784430B2
- Authority
- JP
- Japan
- Prior art keywords
- acrylamide
- methyl
- alkyl
- fluoro
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2013728.7 | 2020-09-01 | ||
| GBGB2013728.7A GB202013728D0 (en) | 2020-09-01 | 2020-09-01 | Novel compounds |
| PCT/GB2021/052261 WO2022049376A1 (en) | 2020-09-01 | 2021-09-01 | Novel compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539694A JP2023539694A (ja) | 2023-09-15 |
| JP2023539694A5 JP2023539694A5 (cg-RX-API-DMAC10.html) | 2024-09-09 |
| JP7784430B2 true JP7784430B2 (ja) | 2025-12-11 |
Family
ID=72749708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537723A Active JP7784430B2 (ja) | 2020-09-01 | 2021-09-01 | 新規化合物 |
Country Status (12)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202013731D0 (en) | 2020-09-01 | 2020-10-14 | Nrg Therapeutics Ltd | Novel cmpounds |
| WO2023209651A1 (en) * | 2022-04-29 | 2023-11-02 | Dong-A St Co., Ltd. | Bicycle compounds as tead inhibitor |
| GB202300833D0 (en) | 2023-01-19 | 2023-03-08 | Nrg Therapeutics Ltd | Novel compounds |
| CN119306612B (zh) * | 2023-07-14 | 2026-03-20 | 中国科学院大连化学物理研究所 | 一种反式氨基茚满的制备方法 |
| CN121866248A (zh) | 2023-09-05 | 2026-04-14 | Nrg治疗有限公司 | 作为mptp抑制剂起作用的吡啶衍生物 |
| GB202410534D0 (en) | 2024-07-18 | 2024-09-04 | Nrg Therapeutics Ltd | Novel method and uses |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012506852A (ja) | 2008-10-27 | 2012-03-22 | コンジェニア・エッセエッレエッレ | ミトコンドリアの膜透過性遷移の阻害剤として有用なアクリルアミド誘導体 |
| WO2012102405A1 (ja) | 2011-01-28 | 2012-08-02 | 佐藤製薬株式会社 | 縮環化合物 |
| JP2017538699A (ja) | 2014-12-05 | 2017-12-28 | エーエヌ2エイチ ディスカバリー リミテッド | パーキンリガーゼ活性化の方法及び組成物 |
| JP2023539695A (ja) | 2020-09-01 | 2023-09-15 | エヌアールジー セラピューティクス エルティーディー | 新規化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2852659B2 (ja) * | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
| JPWO2003020313A1 (ja) | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
| AU2002354476A1 (en) | 2001-12-14 | 2003-06-30 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| JP2006512306A (ja) * | 2002-08-29 | 2006-04-13 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途 |
| JP2006160916A (ja) * | 2004-12-08 | 2006-06-22 | Fuji Photo Film Co Ltd | インクジェット用インク組成物及びインクジェット記録方法 |
| JP5495206B2 (ja) | 2006-10-24 | 2014-05-21 | コンジエニア・ソシエタ・ア・レスポンサビリタ・リミタータ | 変性性組織障害をmptの阻害により防止するための薬剤としてのフェニル置換マレイミド |
| WO2011087051A1 (ja) | 2010-01-14 | 2011-07-21 | 国立大学法人金沢大学 | S1p2受容体アンタゴニストを含む粥状動脈硬化治療薬 |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤 |
| CA2884607A1 (en) | 2015-03-11 | 2016-09-11 | Stealth Peptides International, Inc. | Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions |
| WO2019002624A1 (de) | 2017-06-30 | 2019-01-03 | Kleuser, Burkhard | Mittel zur therapie entzündlicher darmerkrankungen |
-
2020
- 2020-09-01 GB GBGB2013728.7A patent/GB202013728D0/en not_active Ceased
-
2021
- 2021-09-01 MX MX2023002525A patent/MX2023002525A/es unknown
- 2021-09-01 CN CN202180053567.3A patent/CN116096705A/zh active Pending
- 2021-09-01 US US18/023,558 patent/US12630516B2/en active Active
- 2021-09-01 IL IL300900A patent/IL300900A/en unknown
- 2021-09-01 ES ES21769789T patent/ES3055772T3/es active Active
- 2021-09-01 EP EP21769789.5A patent/EP4208442B1/en active Active
- 2021-09-01 AU AU2021337195A patent/AU2021337195A1/en not_active Abandoned
- 2021-09-01 KR KR1020237007646A patent/KR20230069915A/ko not_active Withdrawn
- 2021-09-01 JP JP2023537723A patent/JP7784430B2/ja active Active
- 2021-09-01 CA CA3190645A patent/CA3190645A1/en active Pending
- 2021-09-01 WO PCT/GB2021/052261 patent/WO2022049376A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012506852A (ja) | 2008-10-27 | 2012-03-22 | コンジェニア・エッセエッレエッレ | ミトコンドリアの膜透過性遷移の阻害剤として有用なアクリルアミド誘導体 |
| WO2012102405A1 (ja) | 2011-01-28 | 2012-08-02 | 佐藤製薬株式会社 | 縮環化合物 |
| JP2017538699A (ja) | 2014-12-05 | 2017-12-28 | エーエヌ2エイチ ディスカバリー リミテッド | パーキンリガーゼ活性化の方法及び組成物 |
| JP2023539695A (ja) | 2020-09-01 | 2023-09-15 | エヌアールジー セラピューティクス エルティーディー | 新規化合物 |
Non-Patent Citations (2)
| Title |
|---|
| CAPLUS(STN)[online],1980年,レコード番号(AN):1981:78266;CAS 登録番号:76381-38-9, 76381-39-0, 76381-40-3 |
| REGISTRY (STN) [online],2011.03.13 [検索日 2025.05.08] CAS登録番号 1268319-90-9 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023539694A (ja) | 2023-09-15 |
| WO2022049376A1 (en) | 2022-03-10 |
| US12630516B2 (en) | 2026-05-19 |
| MX2023002525A (es) | 2023-05-17 |
| KR20230069915A (ko) | 2023-05-19 |
| CN116096705A (zh) | 2023-05-09 |
| EP4208442B1 (en) | 2025-10-22 |
| EP4208442A1 (en) | 2023-07-12 |
| US20240067614A1 (en) | 2024-02-29 |
| ES3055772T3 (en) | 2026-02-16 |
| CA3190645A1 (en) | 2022-03-10 |
| GB202013728D0 (en) | 2020-10-14 |
| AU2021337195A1 (en) | 2023-03-02 |
| IL300900A (en) | 2023-04-01 |
| EP4208442C0 (en) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7784431B2 (ja) | 新規化合物 | |
| JP2023539694A (ja) | 新規化合物 | |
| EP3786162B1 (en) | Bipyrazole derivatives as jak inhibitors | |
| WO2020238791A1 (zh) | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2025508898A (ja) | アクリルアミド化合物 | |
| CN118908962A (zh) | 作为hpk1的降解剂的异双功能化合物 | |
| JP2026503519A (ja) | mPTPの阻害剤 | |
| WO2024179393A1 (zh) | 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用 | |
| HK40103736A (en) | Bipyrazole derivatives as jak inhibitors | |
| HK40087858A (en) | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | |
| HK40087858B (en) | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | |
| HK40049209B (en) | Bipyrazole derivatives as jak inhibitors | |
| HK40012259A (en) | Bipyrazole derivatives as jak inhibitors | |
| HK40012259B (en) | Bipyrazole derivatives as jak inhibitors | |
| NZ753637B2 (en) | Bipyrazole derivatives as jak inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240829 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251001 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251111 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251201 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7784430 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |